Lupin-Boehringer announce tie up for diabetes drug

Lupin has signed a marketing agreement with drug maker Boehringer Ingelheim to sell the latter's anti-diabetes drug linaglipitin under its own brand name.

Lupin said the deal will allow it to widen its anti-diabetes portfolio and grow its domestic sales. The branded version of the drug (Ondero and Ondero Met) will be promoted by its 400 member strong diabetes specialty team.

In the past five years Lupin has done similar in-licencing and co-marketing deals for 27 products including agreements with drug makers Eli Lily and Novartis to expand its diabetes portfolio. Domestic business contributes about 24 percent of its consolidated revenue.